Editorial status: Evidence-informed draft for clinician review. Never stop osteoporosis or cancer medication for dental treatment without coordination with the prescribing clinician.

What MRONJ means

Medication-related osteonecrosis of the jaw is a specific clinical condition associated with current or previous exposure to certain bone-modifying or antiangiogenic medicines. Definitions generally require exposed jaw bone, or bone probeable through a fistula, persisting for a defined period in a patient without jaw radiation or obvious jaw metastasis. Diagnosis belongs to clinicians; ordinary delayed healing or pain does not automatically equal MRONJ.

Why the medicine is prescribed matters

The same named drug can carry very different risk depending on indication, dose, route and schedule. High-dose frequent therapy for cancer and skeletal complications generally carries greater MRONJ risk than osteoporosis-dose treatment. Do not give one risk figure for every bisphosphonate or denosumab patient. Record the disease being treated and balance oral risk against fracture or cancer-control benefit.

Medicines associated with risk

Bisphosphonates, denosumab and some antiangiogenic or targeted agents are associated with MRONJ. Brand names vary between countries and patients may not recognise the drug class. Ask for exact name, route, dose, frequency, start and last dose, previous agents and prescriber. A medication list saying only “bone injection” is not adequate before surgery or implant planning.

Risk is not zero, but it is not equal

International consensus estimates historically show much higher incidence in oncology-dose populations than in osteoporosis treatment, where absolute risk is low. Individual risk changes with cumulative exposure, cancer therapy, glucocorticoids, diabetes, smoking, oral inflammation, dentures and surgery. Communicate absolute context without minimising the condition or frightening patients away from medically important therapy.

Dental assessment before therapy

When time allows, complete a comprehensive oral examination before higher-risk bone-modifying treatment begins. Identify infection, non-restorable teeth, periodontal disease, denture trauma and hygiene barriers. Coordinate necessary invasive care and healing with the oncology or medical team. Cancer treatment should not be delayed casually; priorities and timing require multidisciplinary agreement.

Prevention during ongoing therapy

Maintain periodontal health, treat caries early, optimise denture fit and use regular risk-based review. Prevention reduces the need for later extraction. Give patients clear instructions to report exposed bone, non-healing sockets, swelling, drainage, numbness or persistent pain. Avoiding all dentistry is harmful; routine examinations, preventive care, fillings and many endodontic procedures remain important.

Medication history documentation

Record every relevant past and current agent because bisphosphonates can remain in bone after therapy, while denosumab pharmacology differs. Include cancer diagnosis, osteoporosis fracture history, chemotherapy, steroids, diabetes, smoking and renal issues. Contact the prescriber when indication, schedule or treatment risk is unclear. A patient’s memory alone may be insufficient for an irreversible procedure.

Oral infection itself has risk

Leaving an abscess, advanced periodontitis or traumatic prosthesis untreated is not a safe alternative to surgery. Infection and inflammation are associated with MRONJ and can threaten general health. The decision compares controlled treatment with ongoing disease. Early restorative and endodontic care may retain teeth and reduce surgical need, but hopeless teeth require an individual surgical plan.

Non-surgical dental care

Examinations, hygiene care, fillings, crowns and root canal treatment can usually be planned according to ordinary indications with attention to tissue trauma and infection control. Avoid deep subgingival margins and inaccessible designs where possible. Endodontic treatment may retain a restorable tooth, but it should not be used to preserve a fractured or uncontrolled source of infection indefinitely.

Periodontal treatment

Control inflammation with home-care support and professional debridement. Surgical periodontal procedures involve bone and need risk assessment similar to other dentoalveolar surgery. Stabilise disease early and use supportive care. Bleeding on probing alone is not MRONJ, and bone loss from periodontitis should not be relabelled without diagnostic criteria.

Tooth extraction

Extraction may be necessary for non-restorable infection, fracture or severe periodontal disease. Assess medication indication and schedule, local infection, alternatives and surgical complexity. Use an experienced clinician for higher-risk cases, minimise trauma where feasible and plan closure and follow-up. No technique eliminates risk. The patient needs written warning signs and a route for rapid review.

Drug holidays

Evidence that temporary antiresorptive interruption prevents MRONJ is uncertain, and stopping therapy can increase fracture or cancer-related risk. Denosumab interruption can have particular rebound concerns. The dentist must not instruct a drug holiday independently. Any change requires the prescriber, patient and dental surgeon to weigh indication, timing and systemic harm; document the decision and responsibility.

Timing around denosumab

Scheduling proposals vary and must account for the exact product and medical indication. A simplistic internet rule to wait a fixed number of months can be unsafe. Coordinate with the prescriber so dental healing and uninterrupted disease protection are considered. Never delay a scheduled dose or restart it solely on dental advice without medical agreement.

Antibiotic prophylaxis

Antibiotics are not a universal guarantee against MRONJ. Protocols vary by risk and procedure, and evidence for preventive regimens is limited. Use antimicrobials only when clinically justified, considering allergy, interaction, adverse effects and resistance. Meticulous local treatment and follow-up remain necessary. Patients should not self-start leftover antibiotics if a socket is painful.

Platelet concentrates and adjuncts

Platelet-rich products, lasers, ozone and closure techniques have been proposed. Recent evidence does not establish one preventive adjunct as clearly superior. An adjunct should not be marketed as eliminating risk or replacing sound surgery and medical coordination. Consent should distinguish standard care, uncertain benefit and additional cost.

Dental implants

Implant decisions depend strongly on whether therapy is for osteoporosis or cancer, cumulative exposure, oral health and alternative prostheses. Recent consensus suggests osteoporosis-dose antiresorptive therapy does not always need to be stopped before implant placement, but certainty is limited and long-term monitoring is required. Elective implant surgery during high-dose oncology therapy is a different risk context and often avoided.

Existing implants

Do not remove a healthy functioning implant merely because antiresorptive therapy starts. Establish probing and radiographic baselines, control peri-implant inflammation and ensure prosthesis cleanability. Peri-implantitis and surgical intervention can complicate risk. New pain, exposed bone or progressive bone loss requires specialist assessment; not every implant bone change is MRONJ.

Dentures and mucosal trauma

Ill-fitting dentures can ulcerate tissue over thin bone. Review pressure areas, borders, hygiene and overnight wear. Adjust or remake unstable prostheses. A sore spot that fails to heal needs direct examination. Patients should not continue wearing a painful denture to maintain appearance while waiting weeks for routine review.

Diagnostic criteria

Diagnosis considers medication exposure, persistent exposed or probeable bone, duration and exclusion of radiation-related necrosis and metastatic disease. Some patients have non-exposed variants with pain, fistula or radiographic change, which complicates assessment. An oral and maxillofacial surgeon or oral-medicine specialist may be needed. Do not diagnose from a photograph alone.

Symptoms and signs

Possible features include exposed bone, non-healing extraction site, pain, swelling, drainage, fistula, loose teeth, altered sensation and jaw fracture in advanced disease. Some cases are initially painless. These signs overlap infection, periodontal disease, cancer and other conditions. Prompt evaluation is more useful than self-diagnosis based on one symptom.

Imaging

Periapical and panoramic images may show sclerosis, bone destruction or a non-healing socket. CBCT can define three-dimensional extent for selected cases but does not independently prove MRONJ. Imaging choice should answer a clinical question with appropriate radiation dose. In oncology patients, differential diagnosis may require coordination and sometimes tissue assessment.

Staging and management

Staging systems describe clinical extent and help guide care, but recommendations evolve. Management can include antimicrobial rinses, pain and infection control, removal of loose sequestra, conservative surgery or resection in selected disease. Increasing evidence supports surgical approaches for appropriate cases, yet treatment is individualised by stage, symptoms, systemic status and patient goals.

Specialist and medical coordination

The dentist, oral surgeon, oncologist, endocrinologist or primary prescriber should share exact medication and dental information. The prescriber explains systemic consequences of delay or interruption; the dental team explains infection and surgical risk. Patients should not be forced to carry vague verbal messages. Written communication should state the proposed procedure, urgency and healing plan.

Informed consent

Explain baseline risk context, local disease, alternatives, uncertainty, systemic consequences of medication change and warning signs. Avoid claims that signed consent transfers responsibility or that a specific closure method guarantees safety. For elective implants, include non-surgical prosthetic options and future peri-implant maintenance. The patient should have time for questions when urgency permits.

Travel and dental tourism

High-risk patients need continuity beyond the procedure. Before travelling, obtain the medication schedule and prescriber contact, allow healing time and identify local specialist care at home. A short package that ends immediately after extraction or implants is unsafe when delayed exposure or infection may occur. Discharge records should include surgical details and follow-up findings.

After extraction or surgery

Follow written hygiene, diet and medication instructions and attend scheduled review. The clinician assesses soft-tissue coverage, pain, drainage and bone exposure. Healing speed varies; persistent problems need review rather than repeated remote reassurance. Maintain medical treatment unless the authorised prescriber directs otherwise.

Planning before osteoporosis treatment

Osteoporosis therapy prevents fractures that can cause major disability and mortality. A dental check should reduce foreseeable infection without creating unnecessary delay or extracting maintainable teeth. Complete urgent care, explain routine maintenance and send a concise status to the prescriber. A demand for a vague “dental clearance” should be converted into documented findings and outstanding procedures.

Planning before oncology-dose treatment

Time may be limited and systemic therapy has priority. The oncology and dental teams should identify acute infection, non-restorable teeth and prosthesis trauma, decide which procedures can heal before treatment and which can be stabilised non-surgically. Record the planned medication start. Cosmetic and elective implant work should not compete with necessary cancer care and oral infection control.

When treatment has already started

Do not assume every needed extraction must wait indefinitely. Establish urgency, medication schedule, systemic health and non-surgical alternatives, then coordinate an experienced surgical plan when the tooth cannot be retained. Delaying uncontrolled infection can also cause harm. The written discussion should identify who decides medication timing and who provides postoperative surveillance.

Second-opinion comparison

Compare plans using exact drug, indication and exposure rather than a generic “bisphosphonate risk” label. Ask whether the proposed tooth is restorable, whether infection is active, what non-surgical options exist and how follow-up will occur. A plan that promises zero risk is not credible; a plan that refuses all care without assessing disease is also incomplete.

Urgent warning signs

Spreading facial swelling, fever, difficulty swallowing or breathing, uncontrolled bleeding or rapidly worsening systemic illness requires urgent care. Persistent exposed bone, drainage, numbness or a socket that does not heal warrants prompt specialist review even without severe pain. Emergency infection care should not be delayed while teams debate elective drug timing.

Questions for the team

Which exact medicine, dose, route and indication affect my risk?
Is the dental procedure urgent, avoidable or replaceable with a non-surgical option?
Has the prescriber reviewed any proposed timing change?
Who will perform and monitor the procedure?
What warning signs should trigger immediate review?
What is the plan if healing is delayed?

Records to request

Request medication and infusion history, prescriber communication, cancer or osteoporosis indication, risk factors, dental diagnosis, images, surgical consent, operative details, closure method, prescriptions and serial healing notes. For implants, retain system, site and baseline records. Good documentation supports future care without implying that paperwork removes biological risk.

Common errors

Treating every antiresorptive patient as equal risk.
Stopping medication without the prescriber.
Avoiding necessary dentistry and leaving infection untreated.
Promising that antibiotics or PRF eliminate MRONJ.
Calling ordinary socket discomfort osteonecrosis immediately.
Placing elective implants without reviewing indication and dose.
Discharging a travelling patient without monitored healing.

Evidence summary

MRONJ risk depends heavily on drug, indication, dose, route, exposure, systemic therapy and oral disease. Prevention begins with dental stabilisation and lifelong maintenance. Necessary surgery requires individual risk-benefit analysis and coordinated follow-up; evidence does not support an automatic drug holiday or a single superior preventive adjunct. Medication changes belong to the prescribing team, while urgent infection still needs timely source control.

Sources

Prepared as general educational information. Medication and dental decisions require coordination between qualified dental and medical professionals.

Antiresorptive Medications, MRONJ and Dental Treatment